Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Rilzabrutinib for Hives
Recruiting0 awardsPhase 2
Montreal, Quebec
This trial is testing a new oral medication called rilzabrutinib to see if it can help adults with Chronic Spontaneous Urticaria (CSU) who suffer from frequent and severe itching and hives. The medication works by calming the immune system to reduce these symptoms. Participants will be monitored to ensure safety and effectiveness.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service